12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xiaflex: Phase III data

Top-line data from the double-blind, international Phase III IMPRESS I trial in 417 patients with Peyronie's disease showed that twice-weekly Xiaflex every 6 weeks for up to 4 treatment cycles followed by a penile modeling procedure met the co-primary endpoints of reducing penile curvature deformity and improving PDQ bother domain scores from baseline to week 52 vs. placebo. Specifically, Xiaflex reduced mean penile curvature deformity by 37.6% (17.8 degree improvement) vs. 21.3% (10.1 degree improvement) for placebo (p=0.0005) and reduced PDQ bother domain score by 3.3 points (44%) vs. 2 points (27%) for placebo (p=0.0451). The most common adverse events were hematoma, pain and swelling...

Read the full 501 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >